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a  b  s  t  r  a  c  t
LED  illumination  systems  were  found  to  be more  efﬁcacious  than  broad  spectrum  lamps  in recent  phase
III trials  on  photodynamic  treatment  of actinic  keratosis.  However,  a detailed  comparison  of  the  light
doses emitted  at the appropriate  spectral  range  and  its correlation  to photodynamic  effects  is  thus  far
not  available  for  the  most  frequently  used  devices.  Here,  we compared  the  spectral  emissions  of  three
different  PDT  lamps  with  their  potency  of  inducing  cell  death  in  ALA-loaded  A431  cells,  including  a  new
system  equipped  with  more  advanced  LEDs  matching  the photosensitizer  absorption  peak  more  precisely
and emitting  more  homogeneous  light  over  time.  Cells  were  exposed  to two  different  ALA concentrations,
incubated  for  1 or 3 h and  then  illuminated  by one  of  two  different  LED  or a broad-spectrum  system  at
four  different  light  doses,  whereupon  viability  was  assessed.  Maximal  doses  were  selected  in accordancequamous cell carcinoma to clinically  applied  light  doses  in  recent  phase  III studies  and  the  manufacturers’  recommendations.  The
data gathered  here  clearly  demonstrate  that  the two LED  systems  were  signiﬁcantly  more  effective  in
inducing  cell  death  than  the  broad  spectrum  system.  Most  efﬁcient  was  the  newer  LED  system,  in agree-
ment  with  emission  parameters  that  more  accurately  corresponded  to the  photosensitizer’s  absorption
peak.
ublis© 2016  The  Authors.  P
. Background
The efﬁcacy of PDT of skin neoplasia depends on PpIX concen-
ration, oxygen, and light dose (J/cm2). The PpIX absorption peak
round 635 nm seems ideal for dermatologic applications since red
ight penetrates deeper into skin than light hitting absorption peaks
t shorter wavelengths [6].
Several red light systems are routinely used for PDT in Europe.
ost frequent are narrow spectrum LED lamps emitting around
30/635 nm and a broad spectrum lamp emitting a continuous
pectrum above 590. Recent clinical comparisons of the clinical efﬁ-
acies achieved with these lamps proved the higher efﬁcacy of LED
amps [2,3,8].
. AimsThe intention of this study was to analyze and compare commer-
ially available light sources for PDT. Light intensities and spectral
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distributions were measured and correlated to the respective efﬁ-
cacies in killing ALA-loaded A431 cells. The results shall provide
insight into the correlation between the light dose at 635 nm and
in vitro and clinical efﬁcacy.
3. Methods
Lamp types and light doses were applied as follows:
A Gigahertz BTS 256-LED device was used to measure spectral
distribution in W/nm.  Test distances were chosen according to the
respective user manuals: 6 cm for the LED systems and 30 cm for
the broad spectrum lamp.
To record light intensity curves in Lux over 10 min, a Gossen
Mavolux 5032C USB luxmeter was  used at the distances indicated
above.
A431 cells were cultivated and exposed to 5-aminolaevulinic
acid (ALA) as described previously [7] at the intervals and concen-
trations indicated below (Table 2). Times and concentrations were
selected according to previous experiments [7].Experiments were independently repeated on 5 days with every
data point performed in triplicates.
Following incubation, A431 cells were subjected to difference
light doses (Table 1). Immediately afterwards, cell viability was
nder the CC BY-NC-ND license
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Table  1
Light ﬂuence rates.
Lamp Aktilite CL128 BF-RhodoLED PhotoDyn 750
Light ﬂuence in J/cm2 (time) 3 (46 s) 3 (49 s) 7.5 (38 s)
6  (1 min, 32 s) 6 (1 min, 37 s) 15 (1 min, 15 s)
15 (3 min, 51 s) 15 (4 min, 3 s) 75 (6 min, 15 s)
37 (9 min, 30 s) 37 (10 min) 170 (14 min, 10 s)
Table 2
Incubation periods and concentrations.
1 h without 5-ALA (vehicle) 3 h without 5-ALA (vehicle)
1  h at 0.6 mM 5-ALA 3 h at 0.6 mM 5-ALA
1  h at 6.0 mM 5.ALA 3 h at 6.0 mM 5-ALA
Fig. 1. Measurement of physical lamp parameters. (a) Spectral emission of the three
analyzed lamps measured in W/nm.  Light intensities were assessed and plotted
against wavelength in the range of visible light from 380 to 740 nm.  (b) Light inten-
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mity emitted from the three analyzed lamps over the time course of an illumination
eading to an emitted light dose of 37 J/cm2 (LED lamps) or 170 J/cm2 (broad spec-
rum lamp). Intensities were measured in lux and plotted against time in seconds.
easured by adding the MTS-test reagent prepared according to
he supplier’s instructions (Promega). The reagent is converted to a
ormazan product by cellular oxidoreductases. Cells with impaired
iability show a reduced OD450.
Background values were subtracted and the means for each trip-
icate calculated. Cells without ALA were used for normalization.
Results were analyzed using the Mann-Whitney U test. Each
amp was compared to each other lamp in a dose-matched pair
ise fashion. Signiﬁcance criteria were met  at p-values < 0.05.
. Results
Measurements revealed similar spectral distribution and light
ntensity for the two LED systems (Fig. 1a). The light dose is pre-
djusted to 37 J/cm2 in both LED lamps. However, the LEDs used
n BF-RhodoLED provide a peak of spectral emission that is slightly
arrower and higher than that of the Aktilite. This along with a
light shift towards the optimal absorption peak of PpIX at 635 nm
ay  provide a slightly stronger effect of this lamp compared toynamic Therapy 14 (2016) 128–130 129
the Aktilite. Light intensity was more stable over time with the BF-
RhodoLED (Fig. 1b). Light emission around 635 nm with PhotoDyn
750 was below that of both LED lamps by more than one order
of magnitude. The PhotoDyn 750 emits strongly in the infrared
spectrum, thus producing more heat than LED systems.
We  developed a cellular equivalent of dermatological PDT  to
compare the efﬁcacy of the three lamp types (Fig. 2). After incubat-
ing A431 cells for 1 h with 0.6 mM ALA, the subsequent illumination
with one of the three lamps did not notably induce cell death at
any light dose (Fig. 2a). However, when the ALA concentration
was increased 10-fold, the viability declined at higher light doses
(Fig. 2b). Illuminating at either 15 or 37 J/cm2 BF-RhodoLED was
superior to the PhotoDyn device. Aktilite was superior to Photo-
Dyn at 37 J/cm2 only. The difference between the two LED devices
at lower doses may  stem from the more precise emission spectrum
of the LEDs in the BF-RhodoLED around 635 nm.
Longer ALA incubation times (3 h) unraveled a clear light
dependent increase of cell death with the LED lamps, showing sig-
niﬁcantly stronger effects than the broad-spectrum device at both
ALA concentrations (Fig. 2c/d).
5. Conclusion
Phase III studies revealed that PDT with both ALA and MAL is
more effective with LED devices than broad band devices [2,3,8],
and this study was  performed to explain this difference achieved
with standard PDT lamps. At about 635 nm the LED lamps generated
a light intensity of 9 mW/cm2, the broad-spectrum device Photo-
Dyn only 0.3 mW/cm2, which may  be the cause for lower potency
in the induction of cell death in vitro and in phase III trials [1,3,4,8].
A similar difference had been postulated for LED and IPL devices
[5]. While both LED lamps had a comparable impact on cell viabil-
ity, BF-RhodoLED displayed a tendency towards higher efﬁcacy in
this test than Aktilite and achieved a signiﬁcant difference to the
broad-spectrum system at the lower light dose (Fig. 2c). The Photo-
Dyn device was  far less efﬁcacious in this test similar to the results
of phase III trials with these devices. As the maximal light intensi-
ties (37 J/cm2 and 170 J/cm2) matched clinically relevant light doses
[8], these ﬁndings may  explain the outcomes of published phase III
studies.
In conclusion, the abovementioned difference in clinical efﬁcacy
is most likely related to lower light intensity at the relevant wave-
length, where the broad band lamp displays about 30-fold lower
light intensity than the LED lamps. Since this light intensity was
insufﬁcient to induce cell death here, it is surprising that clinical
efﬁcacy is still achieved. In two published phase III trials on PDT
treatment of actinic keratosis using a 10% ALA in a nanoemulsion
formulation (BF-200 ALA), the proportion of completely cleared
patients was 84.8% and 87% with LED (mostly Aktilite) and 71.5%
and 53% with broad band devices [1,3,8]. Unpublished clinical data
on the efﬁcacy of BF-RhodoLED in ﬁeld treatment of actinic kerato-
sis resulted in 91% of completely cleared patients.
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Fig. 2. Induction of cell death. Cell viability was normalized to control conditions in [%] plotted against light dose in J/cm2. The ﬁrst value in the x-axis labels describes the
dose  applied from LED lamps, the second one describes that of the broad spectrum lamp. (a) Cell viability after illumination at different light doses after 1 h incubation with
0.6  mM ALA. (b) Cell viability after illumination with the different light doses after 1 h incubation with 6 mM ALA. (c) Cell viability after illumination with the different light
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